Sonoma Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Sonoma Pharmaceuticals
SNOA Stock  USD 3.06  0.14  4.38%   
Sonoma Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sonoma Pharmaceuticals' valuation are provided below:
Gross Profit
6.4 M
Profit Margin
(0.21)
Market Capitalization
5.4 M
Enterprise Value Revenue
0.1768
Revenue
16.9 M
We have found one hundred twenty available fundamental trend indicators for Sonoma Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Sonoma Pharmaceuticals current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of February 6, 2026, Market Cap is expected to decline to about 16.7 M. In addition to that, Enterprise Value is expected to decline to about 13.2 M

Sonoma Pharmaceuticals Total Revenue

11.15 Million

Check Sonoma Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonoma Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 118 K, Interest Expense of 13.7 K or Selling General Administrative of 13.1 M, as well as many indicators such as Price To Sales Ratio of 0.21, Dividend Yield of 0.0 or PTB Ratio of 0.58. Sonoma financial statements analysis is a perfect complement when working with Sonoma Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Sonoma Stock
Check out the analysis of Sonoma Pharmaceuticals Correlation against competitors.
For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.

Sonoma Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets15.3 M15.7 M15 M
Slightly volatile
Cash5.3 M4.8 M5.9 M
Very volatile
Cash And Short Term Investments5.3 M4.8 M5.9 M
Very volatile
Common Stock Shares Outstanding1.5 M1.4 M378.3 K
Slightly volatile
Liabilities And Stockholders Equity15.3 M15.7 M15 M
Slightly volatile
Other Stockholder Equity145.4 M237.6 M167.6 M
Slightly volatile
Total Current Assets12.6 M14.5 M12.4 M
Slightly volatile
Other Assets1.8 M1.8 M1 M
Slightly volatile
Total Liabilities7.2 M10.7 M7 M
Slightly volatile
Short and Long Term Debt Total260.8 K274.5 K920.4 K
Slightly volatile
Total Current Liabilities3.7 M3.7 M4.2 M
Pretty Stable
Property Plant And Equipment Net264.2 K278.1 K884 K
Slightly volatile
Current Deferred Revenue665.2 K576.9 K860.8 K
Slightly volatile
Accounts Payable1.1 M857.7 K1.1 M
Pretty Stable
Non Current Assets Total893.5 K940.5 K2.6 M
Slightly volatile
Non Currrent Assets Other160.6 K169.1 K539.1 K
Very volatile
Net Receivables2.4 M4.3 M2.6 M
Slightly volatile
Common Stock Total Equity1.7 K1.8 K184.1 K
Slightly volatile
Non Current Liabilities Total6.3 M6 M3.1 M
Slightly volatile
Inventory1.8 M3.4 M2.1 M
Slightly volatile
Other Current Assets651.1 K685.4 K1.6 M
Pretty Stable
Property Plant And Equipment Gross1.7 M2.7 M1.6 M
Slightly volatile
Short Term Debt237.7 K250.2 K559.7 K
Slightly volatile
Common Stock1.7 K1.8 K184.3 K
Slightly volatile
Property Plant Equipment906.4 K815.4 K945.7 K
Slightly volatile
Other Liabilities5.3 M5 M2.3 M
Slightly volatile
Net Tangible Assets9 M7.2 M10.6 M
Slightly volatile
Long Term Debt Total1.6 M1.5 M693.6 K
Slightly volatile
Capital Surpluse189.6 M217.6 M175.9 M
Slightly volatile
Long Term Investments5.9 M4.1 M5.9 M
Slightly volatile
Short and Long Term Debt355.9 K253 K290.1 K
Slightly volatile
Capital Lease Obligations92.9 K97.8 K280.3 K
Pretty Stable
Net Invested Capital7.2 M4.2 M11.3 M
Slightly volatile
Net Working Capital7.6 M7.7 M10.7 M
Slightly volatile
Non Current Liabilities Other2.6 M4.6 M2 M
Slightly volatile

Sonoma Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative13.1 M8.2 M11.7 M
Pretty Stable
Total Revenue11.1 M16.4 M13.7 M
Slightly volatile
Gross Profit4.9 M6.3 M6.2 M
Pretty Stable
Other Operating Expenses21.2 M20.7 M20.7 M
Pretty Stable
Research Development1.7 M1.6 M1.4 M
Pretty Stable
Cost Of Revenue6.5 M10.1 M7.5 M
Slightly volatile
Total Operating Expenses14.9 M10.6 M13.2 M
Pretty Stable
Selling And Marketing Expenses110.7 K171 K133.1 K
Very volatile
Discontinued Operations568.6 K598.5 K3 M
Slightly volatile
Interest Income17.5 K18.4 K40.9 K
Very volatile
Extraordinary Items12.4 M20.6 M13.1 M
Slightly volatile
Reconciled Depreciation210.7 K124.2 K345.4 K
Slightly volatile

Sonoma Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5.4 M2.8 M5.9 M
Pretty Stable
Depreciation118 K124.2 K243.1 K
Slightly volatile
Capital Expenditures68.4 K72 K251.2 K
Slightly volatile
End Period Cash Flow5.6 M4.8 M6.1 M
Pretty Stable
Stock Based Compensation191.5 K201.6 K1.2 M
Slightly volatile
Issuance Of Capital Stock3.4 M2.8 M4.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.210.226.222
Slightly volatile
Days Sales Outstanding87.8811172.1937
Slightly volatile
Stock Based Compensation To Revenue0.01710.0180.1054
Slightly volatile
Capex To Depreciation1.280.671.2357
Slightly volatile
Inventory Turnover5.923.483.9432
Pretty Stable
Days Of Inventory On Hand66.7310997.2522
Slightly volatile
Payables Turnover4.548.336.9152
Slightly volatile
Sales General And Administrative To Revenue0.40.450.4928
Slightly volatile
Research And Ddevelopement To Revenue0.140.150.1064
Very volatile
Capex To Revenue0.00610.00640.0784
Slightly volatile
Cash Per Share4.734.98134
Slightly volatile
Days Payables Outstanding43.0745.3456.185
Slightly volatile
Current Ratio2.342.783.1041
Pretty Stable
Receivables Turnover4.473.425.8758
Slightly volatile
Capex Per Share0.07040.074127.9465
Slightly volatile
Revenue Per Share12.5813.24284
Slightly volatile
Interest Debt Per Share0.270.2878.2515
Slightly volatile
Debt To Assets0.02430.02560.0798
Slightly volatile
Graham Number9711.3 K1.3 K
Slightly volatile
Operating Cycle131195167
Slightly volatile
Days Of Payables Outstanding43.0745.3456.185
Slightly volatile
Long Term Debt To Capitalization0.180.19630.2218
Pretty Stable
Total Debt To Capitalization0.07070.07440.1892
Slightly volatile
Quick Ratio2.012.142.5762
Pretty Stable
Cash Ratio1.771.511.6001
Very volatile
Cash Conversion Cycle168160116
Slightly volatile
Days Of Inventory Outstanding66.7310997.2522
Slightly volatile
Days Of Sales Outstanding87.8811172.1937
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.81.721.1695
Slightly volatile
Fixed Asset Turnover43.741.6219.9758
Slightly volatile
Debt Ratio0.02430.02560.0798
Slightly volatile
Price Sales Ratio0.210.226.222
Slightly volatile
Asset Turnover0.730.940.9719
Slightly volatile
Gross Profit Margin0.250.340.444
Slightly volatile

Sonoma Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap16.7 M17.6 M37.9 M
Slightly volatile
Enterprise Value13.2 M13.9 M32.6 M
Slightly volatile

Sonoma Fundamental Market Drivers

Sonoma Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
19th of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of June 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Sonoma Pharmaceuticals Financial Statements

Sonoma Pharmaceuticals stakeholders use historical fundamental indicators, such as Sonoma Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Sonoma Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sonoma Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Sonoma Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sonoma Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue576.9 K665.2 K
Total Revenue16.4 M11.1 M
Cost Of Revenue10.1 M6.5 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.45  0.40 
Research And Ddevelopement To Revenue 0.15  0.14 
Capex To Revenue 0.01  0.01 
Revenue Per Share 13.24  12.58 
Ebit Per Revenue(0.23)(0.25)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:
How To Invest In Sonoma
Details
Is Sonoma Stock a good investment?
Details
What is Sonoma Pharmaceuticals' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Sonoma Pharmaceuticals Correlation against competitors.
For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Sonoma Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.99)
Revenue Per Share
10.646
Quarterly Revenue Growth
0.566
Return On Assets
(0.14)
Return On Equity
(0.76)
Investors evaluate Sonoma Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sonoma Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Sonoma Pharmaceuticals' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sonoma Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY